Press release
NASH Drugs Market to Reach USD 38.26 Billion by 2034 Driven by Rising Liver Disease Burden & Breakthrough Therapeutic Pipelines
NASH Drugs Market
Market Summary
The NASH Drugs Market is witnessing explosive growth as pharmaceutical companies race to commercialize treatments targeting fibrosis, inflammation, and metabolic dysfunction. NASH affects millions globally and is emerging as a leading cause of liver transplantation. Breakthrough therapeutic classes-including FXR agonists, FGF21 analogs, PPAR agonists, THR-β agonists, CCR2/CCR5 inhibitors, GLP-1 combinations, and anti-fibrotic agents-are advancing rapidly through late-stage pipelines. Improved diagnostic tools such as non-invasive imaging, biomarkers, and AI-based fibrosis assessment are facilitating earlier intervention. North America leads the market due to high disease prevalence, while Asia-Pacific is the fastest-growing region driven by rising metabolic disorders.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73177
Key Takeaways
• 2024 Market Size: USD 5.94 Billion
• 2034 Forecast: USD 38.26 Billion
• CAGR: 20.6% (2025-2034)
• FXR agonists and combination therapies dominating late-stage development
• High unmet clinical need boosting R&D investment
• Asia-Pacific experiencing sharp growth due to increasing obesity and diabetes
Market Drivers
• Growing global burden of NAFLD and NASH
• Increased funding for fibrosis and metabolic disease research
• Pipeline progression of first-in-class and combination therapies
• Advances in non-invasive diagnostics enabling patient identification
• Rising partnership activity between biotech firms and large pharma
Explore Full Report here:
https://exactitudeconsultancy.com/reports/73177/nash-drugs-market
Segmentation Snapshot
By Drug Class
• FXR Agonists
• PPAR Agonists
• THR-β Agonists
• FGF21 Analogs
• GLP-1 Combinations
• CCR2/CCR5 Inhibitors
• Others
By Stage of Treatment
• Early-Stage NASH
• Advanced Fibrosis
• Cirrhotic NASH
By Distribution Channel
• Hospital Pharmacies
• Specialty Clinics
• Retail & Online Pharmacies
By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73177
Recent Developments
• FXR agonists achieving key regulatory milestones.
• Combination regimens (e.g., GLP-1 + FGF21) showing superior fibrosis reduction.
• AI-based diagnostic tools improving staging accuracy for NASH clinical trials.
Expert Quote - Irfan Tamboli, Business Development Executive
"NASH represents one of the highest unmet needs in metabolic disease. Breakthrough drug classes and combination therapies are finally bringing hope to millions of patients worldwide."
Conclusion
The NASH Drugs Market is on a steep growth trajectory through 2034 as innovative metabolic and anti-fibrotic therapies progress toward commercialization. Companies with strong pipelines, biomarker-driven strategies, and combination platforms will dominate this rapidly evolving market.
This report is also available in the following languages : Japanese (NASH治療薬市場), Korean (NASH 약물 시장), Chinese (NASH药物市场), French (Marché des médicaments contre la NASH), German (Markt für NASH-Medikamente), and Italian (Mercato dei farmaci per la NASH), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/73177
Our More Reports:
Cosmetic Surgery Market
https://exactitudeconsultancy.com/reports/73203/cosmetic-surgery-market
Virtual Biopsy Market
https://exactitudeconsultancy.com/reports/73687/virtual-biopsy-market
Sandhoff Disease Market
https://exactitudeconsultancy.com/reports/72045/sandhoff-disease-market
Severe Hypoglycemia Market
https://exactitudeconsultancy.com/reports/72047/severe-hypoglycemia-market
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NASH Drugs Market to Reach USD 38.26 Billion by 2034 Driven by Rising Liver Disease Burden & Breakthrough Therapeutic Pipelines here
News-ID: 4302449 • Views: …
More Releases from Exactitude Consultancy
Bispecific Antibodies Clinical Trials Market to Reach USD 19.84 Billion by 2034 …
Pune, India - December 2025 - The global Bispecific Antibodies Clinical Trials Market, valued at USD 6.72 billion in 2024, is projected to reach USD 19.84 billion by 2034, growing at a strong 11.5% CAGR (2025-2034), according to Exactitude Consultancy. Rising adoption of bispecific antibodies (bsAbs) in oncology, hematology, and immunotherapy is driving rapid expansion of global clinical trial pipelines.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/73175
Market Summary
The Bispecific…
Diabetic Macular Edema (DME) Market Poised for Steady Growth as Anti-VEGF Innova …
The Diabetic Macular Edema (DME) market is moving into a mature but innovation-rich phase. As more patients live longer with diabetes, demand for sight-saving retinal therapies continues to rise. With anti-VEGF drugs, intravitreal steroids, sustained-release implants, and emerging delivery systems such as port-delivery devices and biosimilars, the DME landscape is becoming more competitive, patient-centric, and outcomes-focused.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72052
Keyword Definition
Diabetic Macular Edema (DME) is…
Cystinosis Market Evolves as Novel Therapies, Earlier Diagnosis, and Improved Pa …
The Cystinosis Market, though rare and highly specialized, is gaining strategic importance as advances in treatment, coordinated care models, and patient advocacy change the outlook for affected children and adults. With improved formulations of cystine-depleting drugs, enhanced renal and ocular management, and increasing focus on quality of life, stakeholders are working toward transforming cystinosis from a fatal childhood disorder into a manageable chronic condition.
Download Full PDF Sample Copy of Market…
Somatotropin Deficiency Market Strengthens as Long-Acting Growth Hormone Therapi …
The Somatotropin Deficiency Market is entering a high-innovation cycle as demand rises for safer, more effective, and longer-acting growth hormone therapies. With advancements in recombinant DNA technology, automated injection devices, and pediatric endocrinology screening programs, treatment for growth hormone deficiency is becoming more accessible and patient-friendly worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72048
Keyword Definition
Somatotropin deficiency-commonly known as Growth Hormone Deficiency (GHD)-is a condition characterized by inadequate secretion…
More Releases for NASH
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
